EP0401384B1
(de)
*
|
1988-12-22 |
1996-03-13 |
Kirin-Amgen, Inc. |
Chemisch modifizierte granulocytenkolonie erregender faktor
|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
US5581476A
(en)
*
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
DK1090645T3
(da)
*
|
1994-02-08 |
2006-03-27 |
Amgen Inc |
Oral tilförsel af kemisk modificerede proteiner
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
EP0788375A2
(de)
*
|
1994-11-09 |
1997-08-13 |
Robin Ewart Offord |
Funktionstüchtige polymere für lagespezifische bindung
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
PT858343E
(pt)
|
1995-11-02 |
2004-07-30 |
Schering Corp |
Terapia por infusao continua de uma dose baixa de citoquina
|
TW517067B
(en)
*
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
ES2312179T3
(es)
|
1996-12-06 |
2009-02-16 |
Amgen Inc. |
Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
|
AU5773798A
(en)
*
|
1997-01-29 |
1998-08-18 |
Polymasc Pharmaceuticals Plc |
Pegylation process
|
AU744085B2
(en)
|
1997-06-06 |
2002-02-14 |
Kyowa Hakko Kirin Co., Ltd. |
Chemically modified polypeptides
|
WO1999003887A1
(en)
*
|
1997-07-14 |
1999-01-28 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US20080076706A1
(en)
*
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6017876A
(en)
*
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
NZ507456A
(en)
*
|
1998-04-28 |
2003-10-31 |
Applied Research Systems |
Process and conjugated forms of PEGylated interferon- beta with polyethylene glycol (PEG) wherein the thiol reactive polyol agent is mono-methoxylated
|
CN1230198C
(zh)
*
|
1998-05-15 |
2005-12-07 |
先灵公司 |
给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法
|
NL1009601C2
(nl)
*
|
1998-07-09 |
2000-01-11 |
Univ Utrecht |
Verbinding welke de binding van een eiwit aan mestcellen kan remmen, toepassing van de verbinding voor de bereiding van een geneesmiddel, een farmaceutisch preparaat, een werkwijze voor het diagnostiseren van een ziekte en een selectiewerkwijze.
|
EP1133563A2
(de)
*
|
1998-07-16 |
2001-09-19 |
Hyseq, Inc. |
Verfahren und moleküle in bezug zu dc39-artigen polypeptiden
|
US6783965B1
(en)
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
EP2158923B1
(de)
|
1998-08-06 |
2013-02-27 |
Mountain View Pharmaceuticals, Inc. |
Peg-uricase Konjugate und Verwendung davon
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
EP1121382B9
(de)
*
|
1998-10-16 |
2007-07-04 |
Biogen Idec MA Inc. |
Interferon-beta fusionsproteine und deren verwendungen
|
NZ510689A
(en)
*
|
1998-10-16 |
2003-07-25 |
Biogen Inc |
Polymer conjugates of interferon beta-1a and uses
|
EP1124961B9
(de)
*
|
1998-10-23 |
2010-07-21 |
Kirin-Amgen Inc. |
Thrombopoietin substitute
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
WO2000032772A2
(en)
*
|
1998-11-30 |
2000-06-08 |
Eli Lilly And Company |
Erythropoietic compounds
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
BR122013003013B8
(pt)
|
1999-01-14 |
2021-07-06 |
Bolder Biotechnology Inc |
proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
|
AU2618500A
(en)
*
|
1999-01-29 |
2000-08-18 |
Amgen, Inc. |
Gcsf conjugates
|
SI1157037T1
(en)
*
|
1999-01-29 |
2003-12-31 |
F. Hoffmann-La Roche Ag |
Gcsf conjugates
|
AU2824700A
(en)
*
|
1999-03-01 |
2000-09-21 |
Kyowa Hakko Kogyo Co. Ltd. |
Chemically modified g-csf preparations
|
US6485718B1
(en)
|
1999-04-13 |
2002-11-26 |
Pharmacia Corporation |
Site specific ligation of proteins to synthetic particles
|
US6924264B1
(en)
*
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US7160924B2
(en)
*
|
2002-07-19 |
2007-01-09 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US6348558B1
(en)
|
1999-12-10 |
2002-02-19 |
Shearwater Corporation |
Hydrolytically degradable polymers and hydrogels made therefrom
|
US7074878B1
(en)
*
|
1999-12-10 |
2006-07-11 |
Harris J Milton |
Hydrolytically degradable polymers and hydrogels made therefrom
|
US6646110B2
(en)
*
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
US6555660B2
(en)
*
|
2000-01-10 |
2003-04-29 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
US6831158B2
(en)
*
|
2000-01-10 |
2004-12-14 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
KR100773323B1
(ko)
|
2000-01-10 |
2007-11-05 |
맥시겐 홀딩스 리미티드 |
지-씨에스에프 접합체
|
CA2397347C
(en)
|
2000-02-11 |
2011-07-12 |
Maxygen Aps |
Factor vii or viia-like molecules
|
US7049761B2
(en)
*
|
2000-02-11 |
2006-05-23 |
Altair Engineering, Inc. |
Light tube and power supply circuit
|
EP1129720B1
(de)
|
2000-02-29 |
2004-06-23 |
Pfizer Products Inc. |
Stabilisierter Granulozyten-Kolonie-stimulierender Faktor
|
US20020064820A1
(en)
*
|
2000-03-13 |
2002-05-30 |
Jean-Michel Dayer |
Apo-A-I regulation of T-cell signaling
|
AU2001289307A1
(en)
*
|
2000-04-06 |
2001-10-23 |
Pharmacia Corporation |
Chemically-modified myelopoietin conjugates
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
US6939541B2
(en)
*
|
2000-04-14 |
2005-09-06 |
University Of South Carolina |
Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase
|
AU5717301A
(en)
|
2000-04-21 |
2001-11-07 |
Amgen Inc |
Apo-ai/aii peptide derivatives
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
US20030211094A1
(en)
*
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
EP1299415A4
(de)
*
|
2000-07-12 |
2005-01-19 |
Gryphon Therapeutics Inc |
Modulatoren von chemokinrezeptoren, deren herstellung und verwendung
|
KR20030046411A
(ko)
*
|
2000-09-08 |
2003-06-12 |
그리폰 테라퓨틱스, 인코포레이티드 |
'위'-천연 화학적 라이게이션
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
ATE516820T1
(de)
*
|
2000-09-29 |
2011-08-15 |
Schering Corp |
Pegyliertes interleukin 10
|
EP1333036B1
(de)
*
|
2000-10-16 |
2009-01-21 |
Chugai Seiyaku Kabushiki Kaisha |
Peg-modifiziertes erythropoietin
|
JP2004534721A
(ja)
*
|
2000-10-31 |
2004-11-18 |
ピーアール ファーマシューティカルズ,インク. |
生理活性分子の向上した送達のための方法及び組成物
|
WO2002036626A1
(en)
*
|
2000-11-02 |
2002-05-10 |
Maxygen Aps |
Single-chain multimeric polypeptides
|
CN1321134C
(zh)
*
|
2000-11-23 |
2007-06-13 |
赵剑 |
一种生物活性蛋白质的非均一制品及其制备方法
|
JP2004515533A
(ja)
*
|
2000-12-14 |
2004-05-27 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
代謝障害を治療するためのペプチドyyおよびペプチドyyアゴニスト
|
TW593427B
(en)
*
|
2000-12-18 |
2004-06-21 |
Nektar Therapeutics Al Corp |
Synthesis of high molecular weight non-peptidic polymer derivatives
|
US7053150B2
(en)
|
2000-12-18 |
2006-05-30 |
Nektar Therapeutics Al, Corporation |
Segmented polymers and their conjugates
|
BR0116381A
(pt)
|
2000-12-20 |
2004-02-25 |
Hoffmann La Roche |
Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina
|
US7442370B2
(en)
|
2001-02-01 |
2008-10-28 |
Biogen Idec Ma Inc. |
Polymer conjugates of mutated neublastin
|
MXPA03007002A
(es)
*
|
2001-02-06 |
2003-11-18 |
Merck Patent Gmbh |
Factor estimulante de colonia de granulocitos (g-csf) modificado con inmunogenicidad reducida.
|
EP1234583A1
(de)
*
|
2001-02-23 |
2002-08-28 |
F. Hoffmann-La Roche Ag |
PEG-Konjugate des HGF-NK4
|
WO2002074806A2
(en)
|
2001-02-27 |
2002-09-26 |
Maxygen Aps |
New interferon beta-like molecules
|
US7276580B2
(en)
|
2001-03-12 |
2007-10-02 |
Biogen Idec Ma Inc. |
Neurotrophic factors
|
CA2445947A1
(en)
*
|
2001-04-30 |
2002-11-07 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
US7247618B2
(en)
*
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
ES2387546T3
(es)
|
2001-05-11 |
2012-09-25 |
Amgen Inc. |
Péptidos y moléculas relacionadas que se unen a TALL-1
|
ATE414711T1
(de)
*
|
2001-06-28 |
2008-12-15 |
Mountain View Pharmaceuticals |
Polymerstabilisierte proteinasen
|
WO2003006501A2
(en)
|
2001-07-11 |
2003-01-23 |
Maxygen Holdings, Ltd. |
G-csf conjugates
|
US20040077835A1
(en)
*
|
2001-07-12 |
2004-04-22 |
Robin Offord |
Chemokine receptor modulators, production and use
|
BR0213103A
(pt)
*
|
2001-10-05 |
2004-09-21 |
Intermune Inc |
Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico
|
US7084257B2
(en)
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
US6908963B2
(en)
*
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
US7214660B2
(en)
*
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
PT1436012T
(pt)
|
2001-10-18 |
2018-03-27 |
Nektar Therapeutics |
Conjugados poliméricos de antagonistas de opióides
|
JPWO2003043651A1
(ja)
*
|
2001-11-19 |
2005-03-10 |
協和醗酵工業株式会社 |
多分化能幹細胞を組織から末梢血へ動員する薬剤
|
JP2005525302A
(ja)
*
|
2001-11-20 |
2005-08-25 |
ファルマシア・コーポレーション |
化学的に修飾されたヒト成長ホルモンコンジュゲート
|
US20030171285A1
(en)
*
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
KR100480432B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
G-csf와 폴리에틸렌글리콜 유도체의 배합체
|
JP2005517648A
(ja)
*
|
2001-12-07 |
2005-06-16 |
インターミューン インコーポレイテッド |
肝炎ウイルス感染症を治療するための組成物および方法
|
ATE410459T1
(de)
*
|
2002-01-14 |
2008-10-15 |
Gen Hospital Corp |
Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
|
ES2774801T3
(es)
|
2002-01-18 |
2020-07-22 |
Biogen Ma Inc |
Compuestos de polímero de polialquileno y usos de los mismos
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
US20030191056A1
(en)
*
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
US20030199464A1
(en)
*
|
2002-04-23 |
2003-10-23 |
Silviu Itescu |
Regeneration of endogenous myocardial tissue by induction of neovascularization
|
US20060122106A1
(en)
*
|
2002-06-14 |
2006-06-08 |
Amylin Pharmaceuticals, Inc |
Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
AU2003254023A1
(en)
|
2002-07-19 |
2004-02-09 |
The General Hospital Corporation |
Oxime conjugates and methods for their formation and use
|
US20040136992A1
(en)
|
2002-08-28 |
2004-07-15 |
Burton Paul B. J. |
Compositions and method for treating cardiovascular disease
|
EA200500475A1
(ru)
|
2002-09-09 |
2005-10-27 |
Нектар Терапеутикс Ал, Корпорейшн |
Водорастворимые полимерные алканалы
|
US8129330B2
(en)
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
JP2004196770A
(ja)
*
|
2002-10-24 |
2004-07-15 |
Effector Cell Institute Inc |
樹状細胞前駆体の血中レベル上昇剤
|
US20050075279A1
(en)
*
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
US7314613B2
(en)
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
TWI281864B
(en)
*
|
2002-11-20 |
2007-06-01 |
Pharmacia Corp |
N-terminally monopegylated human growth hormone conjugates and process for their preparation
|
WO2004060300A2
(en)
*
|
2002-12-26 |
2004-07-22 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
CA2511814C
(en)
*
|
2002-12-26 |
2015-02-17 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates of interferon-beta with enhanced biological potency
|
WO2004063221A1
(ja)
|
2002-12-26 |
2004-07-29 |
Takeda Pharmaceutical Company Limited |
メタスチン誘導体およびその用途
|
AU2003303595A1
(en)
*
|
2002-12-30 |
2004-07-29 |
Gryphon Therapeutics, Inc. |
Water-soluble thioester and selenoester compounds and methods for making and using the same
|
US7803362B2
(en)
*
|
2003-01-24 |
2010-09-28 |
Synageva Biopharma Corp. |
Glycosylated interferon alpha
|
CA2516552A1
(en)
*
|
2003-02-26 |
2004-09-10 |
Intermune, Inc. |
Polyethylene glycol modified interferon compositions and methods of use thereof
|
US20070077225A1
(en)
*
|
2003-02-28 |
2007-04-05 |
Blatt Lawrence M |
Continuous delivery methods for treating hepatitis virus infection
|
DK2163643T3
(en)
|
2003-03-05 |
2015-03-23 |
Halozyme Inc |
Soluble hyaluronidaseglycoprotein (sHASEGP), process for preparing the same, pharmaceutical compositions and uses thereof covered
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
WO2004083258A2
(en)
|
2003-03-14 |
2004-09-30 |
Neose Technologies Inc. |
Branched water-soluble polymers and their conjugates
|
JP2006521372A
(ja)
*
|
2003-03-28 |
2006-09-21 |
バイオポリメド インコーポレーテッド |
生物学的活性物質と生体適合性高分子の1:1接合体、この製造方法とこれを含む薬学組成物
|
US20060134736A1
(en)
*
|
2003-03-28 |
2006-06-22 |
Jacobs John W |
Human growth hormone conjugated with biocompatible polymer
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
CA2520875A1
(en)
|
2003-03-31 |
2004-10-21 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
CA2522345A1
(en)
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
BR122016021907B8
(pt)
|
2003-04-11 |
2021-07-27 |
Antriabio Inc |
conjugado de insulina-peg, microesfera de poli(lactídioco-glicolídio), formulação de liberação de droga, e uso
|
EP1613274B1
(de)
|
2003-04-15 |
2010-03-03 |
GlaxoSmithKline LLC |
Humane il-18 substitutionsmutanten und deren konjugate
|
ATE433759T1
(de)
|
2003-04-18 |
2009-07-15 |
Biogen Idec Inc |
Polymerkonjugiertes glycosiliertes neublastin
|
EP1633317A4
(de)
|
2003-05-16 |
2008-08-20 |
Intermune Inc |
Synthetische chemokin-rezeptor-liganden und anwendungsverfahren dafür
|
DK1656410T3
(da)
|
2003-07-22 |
2010-06-28 |
Nektar Therapeutics |
Fremgangsmåde til fremstillilng af funktionaliserede polymere fra polymeralkoholer
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
ES2383328T3
(es)
|
2003-07-25 |
2012-06-20 |
Amgen, Inc |
Métodos relacionados con LDCAM y CRTAM
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
PL1666496T3
(pl)
*
|
2003-08-25 |
2014-08-29 |
Toray Industries |
Kompozyt interferonu beta
|
GB0320638D0
(en)
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
LT1675622T
(lt)
|
2003-09-17 |
2017-09-11 |
Nektar Therapeutics |
Daugiašakio polimero provaistai
|
UY28525A1
(es)
*
|
2003-09-22 |
2005-04-29 |
Boehringer Ingelheim Int |
Péptidos macrociclicos activos contra en virus de la hepatitis c
|
SG176455A1
(en)
*
|
2003-10-09 |
2011-12-29 |
Ambrx Inc |
Polymer derivatives
|
EP1673387B1
(de)
|
2003-10-10 |
2010-09-15 |
Novo Nordisk A/S |
Il-21-derivate
|
EP1675871A2
(de)
|
2003-10-10 |
2006-07-05 |
Xencor Inc. |
Tnf-alpha-varianten auf proteinbasis zur behandlung von erkrankungen in verbindung mit tnf-alpha
|
CA2540858C
(en)
|
2003-10-14 |
2009-12-08 |
Intermune, Inc. |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
|
ES2428358T3
(es)
|
2003-10-17 |
2013-11-07 |
Novo Nordisk A/S |
Terapia de combinación
|
US7407973B2
(en)
*
|
2003-10-24 |
2008-08-05 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
US7220407B2
(en)
*
|
2003-10-27 |
2007-05-22 |
Amgen Inc. |
G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
|
US8637650B2
(en)
|
2003-11-05 |
2014-01-28 |
Genovoxx Gmbh |
Macromolecular nucleotide compounds and methods for using the same
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
WO2005053730A1
(ja)
*
|
2003-12-05 |
2005-06-16 |
Kirin Beer Kabushiki Kaisha |
末期心不全治療剤
|
WO2005067963A1
(en)
*
|
2003-12-23 |
2005-07-28 |
Intermune, Inc. |
Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
WO2005070138A2
(en)
|
2004-01-08 |
2005-08-04 |
Neose Technologies, Inc. |
O-linked glycosylation of peptides
|
EP1730167B1
(de)
*
|
2004-01-21 |
2011-01-12 |
Boehringer Ingelheim International GmbH |
Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
|
AU2005209926B2
(en)
|
2004-02-02 |
2007-09-06 |
Ambrx, Inc. |
Modified human four helical bundle polypeptides and their uses
|
EP2422807A3
(de)
|
2004-02-11 |
2012-05-30 |
Amylin Pharmaceuticals Inc. |
Hybridpolypeptide mit auswahlbaren Eigenschaften
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
EP2335716A3
(de)
*
|
2004-02-11 |
2011-10-19 |
Amylin Pharmaceuticals Inc. |
Pankreas-polypeptidfamilienmotive und diese enthaltende polypeptide
|
JP2007526317A
(ja)
*
|
2004-03-01 |
2007-09-13 |
エンゾン ファーマスーティカルズ インコーポレイテッド |
インターフェロン−ベータ・ポリマー結合体
|
JP2007530569A
(ja)
*
|
2004-03-23 |
2007-11-01 |
アムジエン・インコーポレーテツド |
化学修飾タンパク質組成物及び方法
|
WO2005115477A2
(en)
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
EP1586334A1
(de)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF Konjugate mit PEG
|
CA2566247A1
(en)
|
2004-05-19 |
2005-12-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
US20060018875A1
(en)
*
|
2004-06-14 |
2006-01-26 |
Blatt Lawrence M |
Interferon compositions and methods of use thereof
|
EP1771205B1
(de)
|
2004-06-18 |
2016-10-26 |
Ambrx, Inc. |
Neuartige antigen-bindende polypeptide und ihre verwendungen
|
SG153865A1
(en)
|
2004-06-25 |
2009-07-29 |
Takeda Pharmaceutical |
Metastin derivatives and use thereof
|
US20060029573A1
(en)
*
|
2004-06-30 |
2006-02-09 |
Chun Shen |
Pegylated interferon alpha-1b
|
US8143380B2
(en)
*
|
2004-07-08 |
2012-03-27 |
Amgen Inc. |
Therapeutic peptides
|
WO2006010143A2
(en)
|
2004-07-13 |
2006-01-26 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
|
AU2005327906B2
(en)
|
2004-07-21 |
2010-05-13 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
CN101123978B
(zh)
|
2004-08-19 |
2012-12-12 |
比奥根艾迪克Ma公司 |
神经胚素变体
|
BRPI0514534A
(pt)
|
2004-08-19 |
2008-06-17 |
Biogen Idec Inc |
variantes de neublastina
|
WO2006031811A2
(en)
|
2004-09-10 |
2006-03-23 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
EP1799713B1
(de)
|
2004-09-23 |
2014-11-05 |
VasGene Therapeutics, Inc. |
Polypeptidverbindungen zur hemmung von angiogenese und tumorwachstum
|
ES2566670T3
(es)
|
2004-10-29 |
2016-04-14 |
Ratiopharm Gmbh |
Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
|
US20060153799A1
(en)
*
|
2004-11-05 |
2006-07-13 |
Northwestern University |
Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
|
JP5743371B2
(ja)
|
2004-12-13 |
2015-07-01 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
|
EP2284191A3
(de)
|
2004-12-22 |
2011-07-20 |
Ambrx, Inc. |
Prozess zur Herstellung von hGH
|
US7638491B2
(en)
|
2004-12-22 |
2009-12-29 |
Ambrx, Inc. |
Therapies using non-natural amino acids and polypeptides
|
NZ555386A
(en)
|
2004-12-22 |
2011-01-28 |
Ambrx Inc |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
MX2007007591A
(es)
*
|
2004-12-22 |
2007-07-25 |
Ambrx Inc |
Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
|
EP1674113A1
(de)
|
2004-12-22 |
2006-06-28 |
F. Hoffmann-La Roche Ag |
Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
|
ATE541934T1
(de)
*
|
2004-12-22 |
2012-02-15 |
Ambrx Inc |
Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
|
AU2006203792B2
(en)
|
2005-01-10 |
2011-11-03 |
Ratiopharm Gmbh |
Glycopegylated Granulocyte Colony Stimulating Factor
|
JP5735194B2
(ja)
|
2005-01-25 |
2015-06-17 |
セル セラピューティクス インコーポレーテッド |
改善された生体内半減期を有する生物学的に活性なタンパク質
|
US7662781B2
(en)
*
|
2005-01-31 |
2010-02-16 |
Eci, Inc. |
Immunopotentiating agent
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
CA2597649A1
(en)
*
|
2005-02-11 |
2006-08-17 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
WO2006094530A1
(en)
*
|
2005-03-11 |
2006-09-14 |
Siegfried Ltd. |
Di-polymer protein conjugates and processes for their preparation
|
WO2007010552A2
(en)
*
|
2005-03-17 |
2007-01-25 |
Serum Institute Of India Limited |
N- terminal peg conjugate of erythropoietin
|
JP5114381B2
(ja)
|
2005-03-31 |
2013-01-09 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
精神疾患および障害治療用アミリンおよびアミリンアゴニスト
|
EP1868652A2
(de)
|
2005-04-05 |
2007-12-26 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Verfahren zur abschirmung von funktionalen stellen oder epitopen auf proteinen
|
US20070154992A1
(en)
|
2005-04-08 |
2007-07-05 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
ES2538357T3
(es)
|
2005-04-11 |
2015-06-19 |
Crealta Pharmaceuticals Llc |
Formas variantes de urato oxidasa y uso de las mismas
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
MX2007014524A
(es)
|
2005-05-18 |
2008-02-07 |
Maxygen Inc |
Polipeptidos desarrollados de interferon-alfa.
|
JP5216580B2
(ja)
|
2005-05-25 |
2013-06-19 |
ノヴォ ノルディスク アー/エス |
グリコペグ化第ix因子
|
JP5137821B2
(ja)
*
|
2005-06-01 |
2013-02-06 |
マキシジェン, インコーポレイテッド |
Peg化されたg−csfポリペプチドおよびその製造方法
|
JP2008545754A
(ja)
*
|
2005-06-01 |
2008-12-18 |
アルザ・コーポレーシヨン |
ポリエチレングリコール試薬をアシル化するためのバイオコンジュゲーション反応
|
WO2007009208A1
(en)
*
|
2005-06-02 |
2007-01-25 |
Cangene Corporation |
Poly(ethylene glocol) modified human gm-csf with increased biological activity
|
CA2609205A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
KR100694994B1
(ko)
*
|
2005-06-13 |
2007-03-14 |
씨제이 주식회사 |
사람 과립구 콜로니 형성인자 동종체
|
WO2006135930A2
(en)
*
|
2005-06-13 |
2006-12-21 |
Nastech Pharmaceutical Company Inc. |
Transmucosal delivery of peptide derivatives
|
KR20080033274A
(ko)
|
2005-06-17 |
2008-04-16 |
노파르티스 아게 |
Hcv에서 상글리페린의 용도
|
US8633300B2
(en)
|
2005-06-17 |
2014-01-21 |
Novo Nordisk Healthcare Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
US7695710B2
(en)
*
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
KR20080037656A
(ko)
*
|
2005-06-20 |
2008-04-30 |
펩젠 코포레이션 |
저독성의 장시간 순환하는 사람 인터페론-알파 유사체 및인터페론 타우의 키메라
|
WO2007011802A1
(en)
*
|
2005-07-18 |
2007-01-25 |
Nektar Therapeutics Al, Corporation |
Method for preparing branched functionalized polymers using branched polyol cores
|
KR100735784B1
(ko)
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
|
EA019888B1
(ru)
|
2005-07-25 |
2014-07-30 |
Интермьюн, Инк. |
Промежуточное соединение для получения макроциклических ингибиторов репликации вируса гепатита с и способ его синтеза
|
WO2007015591A1
(en)
*
|
2005-08-02 |
2007-02-08 |
Cheil Industries Inc. |
Epoxy resin composition for packaging semiconductor device
|
KR20080033439A
(ko)
*
|
2005-08-04 |
2008-04-16 |
넥타르 테라퓨틱스 에이엘, 코포레이션 |
G-csf 부분 및 중합체의 컨주게이트
|
EP1922336B1
(de)
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Hybridpolypeptide mit auswählbaren eigenschaften
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
CN103103238B
(zh)
|
2005-08-18 |
2016-08-10 |
Ambrx公司 |
一种在细胞中制造在特定位置处具有所选氨基酸的抗体或抗体片段多肽的方法
|
DK2347762T3
(da)
|
2005-08-19 |
2019-06-11 |
Amylin Pharmaceuticals Llc |
Exendin til behandling af diabetes og reduktion af kropsvægt
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
DK1999129T3
(da)
|
2005-10-11 |
2011-02-07 |
Intermune Inc |
Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus
|
WO2007047303A2
(en)
*
|
2005-10-12 |
2007-04-26 |
Alvine Pharmaceuticals, Inc. |
Pegylated glutenase polypeptides
|
JP5905184B2
(ja)
|
2005-10-13 |
2016-04-20 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. |
自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
|
US8168592B2
(en)
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
CN101291684A
(zh)
*
|
2005-10-21 |
2008-10-22 |
阿维季尼克斯股份有限公司 |
甘醇化和糖基化的禽类来源的治疗性蛋白
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
PT1954710E
(pt)
*
|
2005-11-08 |
2011-06-07 |
Ambrx Inc |
Aceleradores para a modificação de aminoácidos nãonaturais e polipeptídeos de aminoácidos não-naturais
|
AR056806A1
(es)
|
2005-11-14 |
2007-10-24 |
Amgen Inc |
Moleculas quimericas de anticuerpo rankl- pth/ pthrp
|
WO2007059312A2
(en)
*
|
2005-11-16 |
2007-05-24 |
Ambrx, Inc. |
Methods and compositions comprising non-natural amino acids
|
AU2006326404B2
(en)
*
|
2005-12-14 |
2011-11-03 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
US8404643B2
(en)
|
2005-12-22 |
2013-03-26 |
Takeda Pharmaceutical Company Limited |
Metastin derivatives and use thereof
|
CA2841386A1
(en)
|
2005-12-30 |
2007-07-12 |
Zensun (Shanghai) Science & Technology Limited |
Extended release of neuregulin for improved cardiac function
|
CA2636914C
(en)
|
2006-01-12 |
2016-08-09 |
Kuniaki Yoshioka |
Oral composition containing interferon-.alpha.
|
CN100475270C
(zh)
*
|
2006-01-20 |
2009-04-08 |
清华大学 |
一种治疗肿瘤的药物及其应用
|
AR059193A1
(es)
|
2006-01-31 |
2008-03-12 |
Bayer Schering Pharma Ag |
Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
|
JP5312050B2
(ja)
|
2006-02-21 |
2013-10-09 |
ネクター セラピューティクス |
分割型の分解性重合体とそれから生成される複合体
|
TWI501774B
(zh)
|
2006-02-27 |
2015-10-01 |
Biogen Idec Inc |
神經性病症之治療
|
EP2010569A4
(de)
|
2006-03-20 |
2009-09-09 |
Xoma Technology Ltd |
Für gastrin spezifische humane antikörper, materialien und methoden
|
EP2007538A4
(de)
*
|
2006-03-31 |
2011-04-20 |
Centocor Ortho Biotech Inc |
Bindungspartner mit modifzierten immunglobulindomänen für verlängerte halbwertzeit
|
RU2448976C2
(ru)
|
2006-04-11 |
2012-04-27 |
Новартис Аг |
Ингибиторы hcv/вич и их применение
|
JO3324B1
(ar)
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
|
WO2007133778A2
(en)
*
|
2006-05-12 |
2007-11-22 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
WO2007136752A2
(en)
|
2006-05-19 |
2007-11-29 |
Glycofi, Inc. |
Erythropoietin compositions
|
AU2007253264A1
(en)
|
2006-05-24 |
2007-11-29 |
Novo Nordisk Health Care Ag |
Factor IX analogues having prolonged in vivo half life
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
EP2044097A4
(de)
*
|
2006-06-23 |
2010-10-06 |
Quintessence Biosciences Inc |
Modifizierte ribonukleasen
|
ES2376396T3
(es)
|
2006-06-26 |
2012-03-13 |
Amgen Inc. |
Método para tratar aterosclerosis.
|
JP2009543868A
(ja)
|
2006-07-17 |
2009-12-10 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
癌治療に関する方法および組成物
|
US20080274958A1
(en)
|
2006-07-21 |
2008-11-06 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
US10300144B2
(en)
|
2006-07-25 |
2019-05-28 |
Lipoxen Technologies Limited |
N-terminal polysialylation
|
GB0615067D0
(en)
*
|
2006-07-28 |
2006-09-06 |
Ttp Communications Ltd |
Reconfigurable signal processing scheme
|
JP5723528B2
(ja)
|
2006-08-04 |
2015-05-27 |
プロロング ファーマシューティカルズ エルエルシー |
修飾されたエリスロポエチン
|
ITMI20061624A1
(it)
*
|
2006-08-11 |
2008-02-12 |
Bioker Srl |
Mono-coniugati sito-specifici di g-csf
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
CL2007002502A1
(es)
|
2006-08-31 |
2008-05-30 |
Hoffmann La Roche |
Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
|
CA2658736C
(en)
*
|
2006-08-31 |
2014-08-12 |
F. Hoffman-La Roche Ag |
Method for the production of insulin-like growth factor-i
|
WO2008030613A2
(en)
*
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Hybrid suppressor trna for vertebrate cells
|
AU2007292893B2
(en)
*
|
2006-09-08 |
2012-03-01 |
Ambrx, Inc. |
Suppressor tRNA transcription in vertebrate cells
|
AU2007292903B2
(en)
|
2006-09-08 |
2012-03-29 |
Ambrx, Inc. |
Modified human plasma polypeptide or Fc scaffolds and their uses
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
ES2606034T3
(es)
*
|
2006-09-28 |
2017-03-17 |
Merck Sharp & Dohme Corp. |
IL-10 pegilada para uso en el tratamiento de linfoma
|
WO2008057683A2
(en)
|
2006-10-03 |
2008-05-15 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
RU2460543C2
(ru)
*
|
2006-10-04 |
2012-09-10 |
Ново Нордиск А/С |
Глицерин-связанные пэгилированные сахара и гликопептиды
|
WO2008051383A2
(en)
*
|
2006-10-19 |
2008-05-02 |
Amgen Inc. |
Use of alcohol co-solvents to improve pegylation reaction yields
|
TWI404726B
(zh)
|
2006-10-25 |
2013-08-11 |
Takeda Pharmaceutical |
腫瘤轉移抑制素衍生物及其用途
|
US7825093B2
(en)
|
2006-10-25 |
2010-11-02 |
Amgen Inc. |
Methods of using OSK1 peptide analogs
|
KR101079993B1
(ko)
*
|
2006-11-17 |
2011-11-04 |
동아제약주식회사 |
폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
|
US8470332B2
(en)
|
2006-11-22 |
2013-06-25 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
JP5484063B2
(ja)
|
2006-12-08 |
2014-05-07 |
レキシコン ファーマシューティカルズ インコーポレーテッド |
Angptl3に対するモノクローナル抗体
|
US20100144599A1
(en)
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
CN101245109B
(zh)
*
|
2007-02-12 |
2011-12-14 |
杭州九源基因工程有限公司 |
一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
|
BRPI0809583B1
(pt)
|
2007-03-30 |
2022-02-22 |
Ambrx, Inc |
Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
|
CA2682897C
(en)
|
2007-04-03 |
2016-11-22 |
Biogenerix Ag |
Methods of treatment using glycopegylated g-csf
|
JP2008266219A
(ja)
*
|
2007-04-20 |
2008-11-06 |
National Institute Of Advanced Industrial & Technology |
リジン及びシステイン残基を含まないタンパク質
|
JP5583005B2
(ja)
|
2007-05-01 |
2014-09-03 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
血管新生を増大させるための組成物および方法
|
WO2008137471A2
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
EP2738257A1
(de)
|
2007-05-22 |
2014-06-04 |
Amgen Inc. |
Zusammensetzungen und Verfahren zur Herstellung bioaktiver Fusionsproteine
|
WO2008151258A2
(en)
*
|
2007-06-04 |
2008-12-11 |
Neose Technologies, Inc. |
O-linked glycosylation using n-acetylglucosaminyl transferases
|
EP2170919B8
(de)
|
2007-06-12 |
2016-01-20 |
ratiopharm GmbH |
Verbessertes verfahren zur herstellung von nukleotidzuckern
|
US20110159523A1
(en)
*
|
2007-06-27 |
2011-06-30 |
Cedars-Sinai Medical Center |
N-terminal specific chemical labeling for proteomics applications
|
PT2489731E
(pt)
|
2007-07-26 |
2014-09-15 |
Amgen Inc |
Enzimas aciltransferase de lecitina-colesterol modificadas
|
CN101352573B
(zh)
*
|
2007-07-27 |
2011-02-09 |
杭州九源基因工程有限公司 |
聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
|
CA2697265A1
(en)
|
2007-08-09 |
2009-02-19 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
CL2008002399A1
(es)
*
|
2007-08-16 |
2009-01-02 |
Pharmaessentia Corp |
Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
|
EP2197919B1
(de)
|
2007-08-27 |
2014-04-09 |
ratiopharm GmbH |
Flüssige formulierung von g-csf-konjugat
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
WO2009046015A2
(en)
*
|
2007-09-30 |
2009-04-09 |
University Of Florida Research Foundation, Inc. |
Combination therapies for treating type 1 diabetes
|
US8697062B2
(en)
*
|
2007-10-08 |
2014-04-15 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapeutics
|
CN101835496B
(zh)
|
2007-10-23 |
2015-11-25 |
尼克塔治疗公司 |
靶向羟基磷灰石的多臂聚合物以及由其制造的偶联物
|
US8946148B2
(en)
*
|
2007-11-20 |
2015-02-03 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
US20110124841A1
(en)
*
|
2007-12-13 |
2011-05-26 |
Monthony James F |
Polypeptides Modified by Protein Trans-Splicing Technology
|
BRPI0821700A2
(pt)
|
2007-12-27 |
2015-06-16 |
Baxter Int |
Métodos para determinar o número de moléculas de polímero fisiologicamente aceitáveis ligadas a uma proteína ou a um complexo de proteína em um conjugado polímero-proteína e para determinar o número de moléculas de polímero fisiologicamente aceitáveis ligadas a uma proteína ou a um complexo de proteína ou livre em solução
|
WO2009120396A2
(en)
*
|
2008-01-08 |
2009-10-01 |
The University Of California |
Compositions and methods for regulating erythropoientin expression and ameliorating anemia and stimulating erythropoiesis
|
JP5647899B2
(ja)
*
|
2008-01-08 |
2015-01-07 |
ラツィオファルム ゲーエムベーハーratiopharm GmbH |
オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
|
US20090183503A1
(en)
*
|
2008-01-18 |
2009-07-23 |
Alberto Verdesi |
Exhaust apparatus
|
AU2009205978B2
(en)
|
2008-01-18 |
2014-04-10 |
Biomarin Pharmaceutical Inc. |
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
|
CN101939443B
(zh)
|
2008-02-08 |
2014-01-29 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
JP5225393B2
(ja)
*
|
2008-02-18 |
2013-07-03 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
水溶性高分子修飾g−csf複合体
|
EP2626080A3
(de)
|
2008-02-27 |
2014-03-05 |
Novo Nordisk A/S |
Konjugierte Faktor-VIII-Moleküle
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
US20110045510A1
(en)
*
|
2008-04-03 |
2011-02-24 |
Kurt Lang |
Pegylated insulin-like-growth-factor assay
|
ES2453946T3
(es)
|
2008-04-03 |
2014-04-09 |
Biosteed Gene Expression Tech. Co., Ltd. |
Hormona del crecimiento modificada con polietilenglicol bicatenario, método de preparación y aplicación de esta
|
KR20100135291A
(ko)
|
2008-04-14 |
2010-12-24 |
할로자임, 아이엔씨 |
히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
ES2552646T3
(es)
|
2008-05-21 |
2015-12-01 |
Amylin Pharmaceuticals, Inc. |
Exendinas para disminuir el colesterol y los triglicéridos
|
EP2291399B1
(de)
|
2008-05-22 |
2014-06-25 |
Bristol-Myers Squibb Company |
Polyvalente proteine mit fibronectin-gerüstdomänen
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
GB0811743D0
(en)
|
2008-06-26 |
2008-07-30 |
Hemosol Biopharma Inc |
Composition
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
UA118536C2
(uk)
|
2008-07-23 |
2019-02-11 |
Амбркс, Інк. |
Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
|
WO2010013762A1
(ja)
*
|
2008-07-30 |
2010-02-04 |
武田薬品工業株式会社 |
メタスチン誘導体およびその用途
|
KR101533757B1
(ko)
*
|
2008-07-31 |
2015-07-03 |
파마이센시아 코퍼레이션 |
펩티드-중합체 접합체
|
AU2009282413B2
(en)
|
2008-08-11 |
2014-07-17 |
Nektar Therapeutics |
Multi-arm polymeric alkanoate conjugates
|
JP5766118B2
(ja)
|
2008-09-11 |
2015-08-19 |
ウェルズ ファーゴ バンク ナショナル アソシエイション |
ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
|
ES2660000T3
(es)
|
2008-09-26 |
2018-03-20 |
Ambrx, Inc. |
Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales
|
BRPI0919403A2
(pt)
|
2008-09-26 |
2017-09-26 |
Ambrx Inc |
polipeptídeos modificados de eritropoetina animal e seus usos
|
EP2334695B1
(de)
|
2008-10-01 |
2015-12-23 |
Quintessence Biosciences, Inc. |
Therapeutische ribonukleasen
|
PE20120021A1
(es)
|
2008-10-10 |
2012-02-10 |
Amgen Inc |
Mutantes fgf21
|
WO2010045321A2
(en)
|
2008-10-15 |
2010-04-22 |
Baxter International Inc. |
Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
|
MX2011004085A
(es)
|
2008-10-17 |
2011-09-27 |
Baxter International |
Factores sanguineos modificados que comprenden un bajo grado de polimero soluble en agua.
|
CA2741209C
(en)
*
|
2008-10-20 |
2016-12-20 |
Usv Limited |
An improved process for pegylation of proteins
|
JP5775820B2
(ja)
*
|
2008-10-21 |
2015-09-09 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
遊離可能peg試薬を有するプロドラッグpegタンパク質結合体において活性成分(インビトロ脱ペグ化)を決定する方法
|
AU2009308909A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Amgen Inc. |
Materials and methods relating to stem cell mobilization by multi-PEGylated granulocyte colony stimulating factor
|
IT1392655B1
(it)
|
2008-11-20 |
2012-03-16 |
Bio Ker S R L |
Site-specific monoconjugated insulinotropic glp-1 peptides.
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
PT3037529T
(pt)
|
2008-12-09 |
2019-05-31 |
Halozyme Inc |
Polipéptidos ph20 estendidos solúveis e suas utilizações
|
PL2356467T3
(pl)
*
|
2008-12-11 |
2013-12-31 |
Baxalta Inc |
Wykrywanie fizjologicznie dopuszczalnych cząsteczek polimeru z zastosowaniem spektroskopii w bliskiej podczerwieni
|
PL2379115T3
(pl)
|
2008-12-17 |
2018-03-30 |
Merck Sharp & Dohme Corp. |
Wytwarzanie i zastosowania mono- i di-peg il-10
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
KR101860572B1
(ko)
|
2009-05-05 |
2018-05-24 |
암젠 인크 |
Fgf21 돌연변이체 및 이의 용도
|
CA2760674A1
(en)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
PT2432489T
(pt)
|
2009-05-20 |
2016-12-07 |
Biomarin Pharm Inc |
Variantes do péptido natriurético de tipo c
|
WO2010148142A1
(en)
|
2009-06-17 |
2010-12-23 |
Amgen Inc. |
Chimeric fgf19 polypeptides and uses thereof
|
BRPI1014942A2
(pt)
|
2009-06-19 |
2019-09-24 |
Medimmune Llc |
"polipeptídeo, ácido nucleico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição farmacêutica, e método para tratar uma doença"
|
NZ597089A
(en)
|
2009-06-25 |
2014-05-30 |
Savient Pharmaceuticals Inc |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
|
EP2459211A1
(de)
|
2009-07-31 |
2012-06-06 |
Medtronic, Inc. |
Kontinuierliche subkutane verabreichung von interferon an hepatitis-c-patienten
|
WO2011034604A2
(en)
|
2009-09-17 |
2011-03-24 |
Baxter Healthcare, S.A. |
Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
|
WO2011038301A2
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
US20120178914A1
(en)
*
|
2009-09-25 |
2012-07-12 |
Vybion, Inc. |
Polypeptide modification
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
WO2011050938A1
(de)
|
2009-10-26 |
2011-05-05 |
Genovoxx Gmbh |
Konjugate von nukleotiden und methoden zu deren anwendung
|
NZ598465A
(en)
|
2009-10-30 |
2013-10-25 |
Boehringer Ingelheim Int |
Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
|
ES2632431T3
(es)
|
2009-10-30 |
2017-09-13 |
Ntf Therapeutics, Inc. |
Moléculas de neurturina mejoradas
|
MX2012005912A
(es)
|
2009-11-23 |
2012-10-05 |
Amylin Pharmaceuticals Inc |
Conjugado de polipeptido.
|
MX2012006406A
(es)
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
WO2011087808A1
(en)
|
2009-12-21 |
2011-07-21 |
Ambrx, Inc. |
Modified bovine somatotropin polypeptides and their uses
|
MX2012006980A
(es)
|
2009-12-21 |
2012-07-17 |
Ambrx Inc |
Polipeptidos de somatotropina porcina modificados y sus usos.
|
US20110152188A1
(en)
*
|
2009-12-23 |
2011-06-23 |
Hanns-Christian Mahler |
Pharmaceutical compositions of igf/i proteins
|
EP2536753B1
(de)
|
2010-02-16 |
2017-12-20 |
Novo Nordisk A/S |
Faktor-VIII-Moleküle mit reduzierter VWF-Bindung
|
EP2542574B1
(de)
|
2010-03-04 |
2017-08-09 |
Pfenex Inc. |
Verfahren zur herstellung eines löslichen und rekombinanten interferonproteins ohne denaturierung
|
AU2011235210B2
(en)
|
2010-04-01 |
2015-07-16 |
Pfenex Inc. |
Methods for G-CSF production in a Pseudomonas host cell
|
EP2558497A2
(de)
|
2010-04-15 |
2013-02-20 |
Amgen Inc. |
Menschlicher fgf-rezeptor und beta-klotho-bindeproteine
|
US8980253B2
(en)
|
2010-04-26 |
2015-03-17 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
|
WO2011139799A2
(en)
|
2010-04-27 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
|
US8993723B2
(en)
|
2010-04-28 |
2015-03-31 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
|
EP2563383B1
(de)
|
2010-04-29 |
2017-03-01 |
Atyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
|
EP2563912B1
(de)
|
2010-04-29 |
2018-09-05 |
aTyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von asparaginyl-trna-synthetasen
|
CN102234310B
(zh)
*
|
2010-04-30 |
2017-02-08 |
杭州九源基因工程有限公司 |
一种聚乙二醇修饰蛋白的分离纯化方法
|
WO2011140135A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
WO2011140132A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
|
CN103096925A
(zh)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
CN102985103A
(zh)
|
2010-05-04 |
2013-03-20 |
Atyr医药公司 |
与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
|
WO2011143274A1
(en)
|
2010-05-10 |
2011-11-17 |
Perseid Therapeutics |
Polypeptide inhibitors of vla4
|
WO2011143482A2
(en)
|
2010-05-14 |
2011-11-17 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
|
CN103119055A
(zh)
|
2010-05-17 |
2013-05-22 |
塞比克斯公司 |
聚乙二醇化c肽
|
JP6027965B2
(ja)
|
2010-05-17 |
2016-11-16 |
エータイアー ファーマ, インコーポレイテッド |
ロイシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
WO2011150133A2
(en)
|
2010-05-26 |
2011-12-01 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
AU2011258106B2
(en)
|
2010-05-27 |
2017-02-23 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
|
AU2011261486B2
(en)
|
2010-06-01 |
2017-02-23 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases
|
WO2011159930A2
(en)
|
2010-06-16 |
2011-12-22 |
Medtronic, Inc. |
Damping systems for stabilizing medications in drug delivery devices
|
CA2803093A1
(en)
|
2010-06-24 |
2011-12-29 |
Panmed Ltd. |
Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
|
AU2011289831C1
(en)
|
2010-07-12 |
2017-06-15 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
|
US20130183280A1
(en)
|
2010-07-15 |
2013-07-18 |
Novo Nordisk A/S |
Stabilized factor viii variants
|
MX348420B
(es)
|
2010-07-20 |
2017-06-12 |
Halozyme Inc |
Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios.
|
AR082319A1
(es)
|
2010-07-22 |
2012-11-28 |
Biomarin Pharm Inc |
Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
RU2446173C1
(ru)
*
|
2010-08-13 |
2012-03-27 |
Зао "Биокад" |
Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
BR112013003522B1
(pt)
|
2010-08-17 |
2021-05-25 |
Ambrx, Inc. |
polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
|
EP2608801B1
(de)
|
2010-08-25 |
2019-08-21 |
aTyr Pharma, Inc. |
Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von tyrosyl-trna-synthetasen
|
JP6042335B2
(ja)
|
2010-09-15 |
2016-12-14 |
ノヴォ ノルディスク アー/エス |
細胞取込みが低下した第viii因子変異体
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
PL3241558T3
(pl)
|
2010-09-28 |
2021-08-30 |
Aegerion Pharmaceuticals, Inc. |
Wysoce rozpuszczalne leptyny
|
JP2013542206A
(ja)
|
2010-10-05 |
2013-11-21 |
ノバルティス アーゲー |
C型肝炎ウイルス感染症の新規治療
|
WO2012048235A1
(en)
|
2010-10-08 |
2012-04-12 |
Novartis Ag |
Vitamin e formulations of sulfamide ns3 inhibitors
|
CN103933577B
(zh)
*
|
2010-10-25 |
2014-12-10 |
北京凯因科技股份有限公司 |
重组集成干扰素变异体聚乙二醇偶联物的制备和应用
|
CN102453089B
(zh)
*
|
2010-10-25 |
2014-06-04 |
北京凯因科技股份有限公司 |
重组集成干扰素变异体聚乙二醇偶联物的制备和应用
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
RU2013123793A
(ru)
|
2010-11-24 |
2014-12-27 |
Лексикон Фармасьютикалз, Инк. |
Антитела, связывающиеся с notum пектинацетилэстеразой
|
MX2013006052A
(es)
|
2010-11-30 |
2013-06-18 |
Novartis Ag |
Nuevos tratamientos de la infeccion por el virus de hepatitis c.
|
CN102485742A
(zh)
*
|
2010-12-02 |
2012-06-06 |
山东新时代药业有限公司 |
一种聚乙二醇单修饰的重组人粒细胞集落刺激因子的制备及分离纯化方法
|
US20140371258A1
(en)
|
2010-12-17 |
2014-12-18 |
Nektar Therapeutics |
Water-Soluble Polymer Conjugates of Topotecan
|
JP5899241B2
(ja)
|
2010-12-21 |
2016-04-06 |
ネクター セラピューティクス |
ペメトレキセドベースの化合物のマルチアームポリマープロドラッグコンジュゲート
|
US20130331443A1
(en)
|
2010-12-22 |
2013-12-12 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
WO2012088445A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
EP2672958A1
(de)
|
2011-02-08 |
2013-12-18 |
Halozyme, Inc. |
Zusammensetzung und lipidformulierung eines hyaluronan-abbauenden enzym und seine verwendung zur behandlung von benigner prostatahyperplasie
|
KR20140145947A
(ko)
|
2011-03-16 |
2014-12-24 |
암젠 인크 |
Nav1.3과 nav1.7의 유효한 선별적 저해제
|
CN103458918A
(zh)
*
|
2011-03-25 |
2013-12-18 |
纽约哥伦比亚大学理事会 |
聚乙二醇化人类hdl粒子和其制造方法
|
CN103476409A
(zh)
|
2011-03-31 |
2013-12-25 |
诺华股份有限公司 |
治疗丙肝病毒感染的阿拉泊韦
|
KR20140010097A
(ko)
|
2011-04-01 |
2014-01-23 |
노파르티스 아게 |
B형 간염 바이러스 단독 감염 또는 델타 간염 바이러스와의 조합 감염 및 연관된 간 질환의 치료
|
SG193908A1
(en)
|
2011-04-13 |
2013-11-29 |
Novartis Ag |
Treatment of hepatitis c virus infection with alisporivir
|
US20140187488A1
(en)
|
2011-05-17 |
2014-07-03 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
US8569462B2
(en)
|
2011-06-03 |
2013-10-29 |
Xoma Technology Ltd. |
Antibodies specific for TGF-beta and methods for treating thereof
|
BR112013032265A2
(pt)
|
2011-06-17 |
2016-12-20 |
Halozyme Inc |
métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
|
US20130011378A1
(en)
|
2011-06-17 |
2013-01-10 |
Tzung-Horng Yang |
Stable formulations of a hyaluronan-degrading enzyme
|
US20130090294A1
(en)
|
2011-06-28 |
2013-04-11 |
Alternative Innovative Technologies Llc |
Novel methods of use of hsp70 for increased performance or treatment of hsp70 related disorders
|
JP2014522641A
(ja)
|
2011-07-01 |
2014-09-08 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
リラキシン融合ポリペプチドおよびその使用
|
PT2717917T
(pt)
|
2011-07-05 |
2016-07-27 |
Bioasis Technologies Inc |
Conjugados de anticorpos p97
|
US20140256621A1
(en)
|
2011-07-08 |
2014-09-11 |
Astrazeneca Pharmaceuticals Lp |
Engineered poypeptides having enhanced duration of action and reduced immunogenicity
|
CN102952067A
(zh)
*
|
2011-08-30 |
2013-03-06 |
苏州欣诺科生物科技有限公司 |
用于蛋白质n端聚乙二醇修饰的吡哆醛衍生物、制备方法及其应用
|
JP2014526441A
(ja)
|
2011-08-31 |
2014-10-06 |
アムジエン・インコーポレーテツド |
1型糖尿病の治療における使用のためのfgf21
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
TW201315742A
(zh)
|
2011-09-26 |
2013-04-16 |
Novartis Ag |
治療代謝病症之雙功能蛋白質
|
UY34346A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de fusión para tratar trastornos metabólicos
|
WO2013045460A1
(en)
|
2011-09-27 |
2013-04-04 |
Novartis Ag |
Alisporivr for treatment of hepatis c virus infection
|
US9937241B2
(en)
|
2011-10-14 |
2018-04-10 |
Alternative Innovative Technologies Llc |
Degradation resistant HSP70 formulations and uses thereof
|
SG11201401797TA
(en)
|
2011-10-24 |
2014-09-26 |
Halozyme Inc |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
US9241869B2
(en)
|
2011-10-25 |
2016-01-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
WO2013067029A2
(en)
|
2011-10-31 |
2013-05-10 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
WO2013075117A2
(en)
|
2011-11-17 |
2013-05-23 |
John Wahren |
Pegylated c-peptide
|
RU2685867C2
(ru)
|
2011-12-15 |
2019-04-23 |
Алтернатив Инновейтив Текнолоджиз Ллц |
Гибридные белки и белковые конъюгаты на основе белка теплового шока-70 (БТШ70) и способы их применения (варианты)
|
LT3130347T
(lt)
|
2011-12-30 |
2019-10-25 |
Halozyme Inc |
Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas
|
IN2014DN06121A
(de)
|
2012-01-30 |
2015-08-14 |
Arecor Ltd |
|
CN104334196B
(zh)
|
2012-02-16 |
2018-04-10 |
Atyr 医药公司 |
用于治疗自身免疫疾病和炎性疾病的组氨酰‑tRNA合成酶
|
SG10201700340WA
(en)
|
2012-02-27 |
2017-03-30 |
Amunix Operating Inc |
Xten conjugate compositions and methods of making same
|
MX2014010209A
(es)
|
2012-02-29 |
2014-11-21 |
Toray Industries |
Agente inhibidor para acumulacion de fluido de la cavidad corporal.
|
LT2822575T
(lt)
|
2012-03-03 |
2020-06-25 |
Immungene, Inc. |
Sukonstruotos antikūno-mutantinio interferono sulietos molekulės
|
JP2015509980A
(ja)
|
2012-03-14 |
2015-04-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法
|
WO2013143581A1
(en)
|
2012-03-28 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in specific patient subgenotype sub-population
|
WO2013149219A2
(en)
|
2012-03-30 |
2013-10-03 |
Sorrento Therapeutics Inc. |
Fully human antibodies that bind to vegfr2
|
JP6042527B2
(ja)
|
2012-04-04 |
2016-12-14 |
ハロザイム インコーポレイテッド |
抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療
|
CN104736168B
(zh)
|
2012-05-31 |
2018-09-21 |
索伦托治疗有限公司 |
与pd-l1结合的抗原结合蛋白
|
EP2859017B1
(de)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
|
CN105051065A
(zh)
|
2012-06-22 |
2015-11-11 |
索伦托治疗有限公司 |
与ccr2结合的抗原结合蛋白
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
WO2014022515A1
(en)
|
2012-07-31 |
2014-02-06 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
CA2890190A1
(en)
|
2012-11-12 |
2014-05-15 |
Redwood Bioscience, Inc. |
Compounds and methods for producing a conjugate
|
WO2014078733A1
(en)
|
2012-11-16 |
2014-05-22 |
The Regents Of The University Of California |
Pictet-spengler ligation for protein chemical modification
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
US9383357B2
(en)
|
2012-12-07 |
2016-07-05 |
Northwestern University |
Biomarker for replicative senescence
|
US20160067347A1
(en)
|
2012-12-20 |
2016-03-10 |
Amgen Inc. |
Apj receptor agonists and uses thereof
|
CN103908660B
(zh)
*
|
2013-01-05 |
2015-02-04 |
石药集团百克(山东)生物制药有限公司 |
一种聚乙二醇修饰的rhG-CSF药物组合物及其制备方法
|
US20150361159A1
(en)
|
2013-02-01 |
2015-12-17 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
CN103113466B
(zh)
*
|
2013-03-01 |
2015-06-03 |
中国科学院过程工程研究所 |
聚乙二醇修饰的重组人干扰素β-1b及制备方法
|
US10344060B2
(en)
|
2013-03-12 |
2019-07-09 |
Amgen Inc. |
Potent and selective inhibitors of Nav1.7
|
WO2014160438A1
(en)
|
2013-03-13 |
2014-10-02 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
RU2535002C2
(ru)
*
|
2013-04-04 |
2014-12-10 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук |
Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
|
CN106913865A
(zh)
|
2013-04-18 |
2017-07-04 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素‑10治疗疾病和病症的方法
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
CA2914837A1
(en)
|
2013-06-17 |
2014-12-24 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
AU2014312190A1
(en)
|
2013-08-28 |
2016-02-18 |
Bioasis Technologies Inc. |
CNS-targeted conjugates of antibodies
|
WO2015031316A1
(en)
|
2013-08-30 |
2015-03-05 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
EA201690490A1
(ru)
|
2013-10-02 |
2016-07-29 |
Новартис Аг |
Миметики инсулиноподобного фактора роста для применения в терапии
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EP3057605A1
(de)
|
2013-10-18 |
2016-08-24 |
Novartis AG |
Verfahren zur behandlung von diabetes und verwandten erkrankungen
|
JP6660297B2
(ja)
|
2013-11-11 |
2020-03-11 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害を処置するためのインターロイキン−10の使用方法
|
WO2015073727A1
(en)
|
2013-11-13 |
2015-05-21 |
Aequus Biopharma, Inc. |
Engineered glycoproteins and uses thereof
|
CA3178867A1
(en)
|
2013-11-27 |
2015-06-04 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
UY35874A
(es)
|
2013-12-12 |
2015-07-31 |
Novartis Ag |
Un proceso para la preparación de una composición de proteínas pegiladas
|
US10188739B2
(en)
|
2014-02-27 |
2019-01-29 |
Xenetic Biosciences, Inc. |
Compositions and methods for administering insulin or insulin-like protein to the brain
|
US10293043B2
(en)
|
2014-06-02 |
2019-05-21 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
ES2950789T3
(es)
|
2014-06-10 |
2023-10-13 |
Amgen Inc |
Polipéptidos de apelina
|
CN111187338A
(zh)
|
2014-06-12 |
2020-05-22 |
Ra制药公司 |
补体活性的调节
|
CA2958673A1
(en)
|
2014-08-22 |
2016-02-25 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind cxcr3
|
PL3186281T3
(pl)
|
2014-08-28 |
2019-10-31 |
Halozyme Inc |
Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
|
EP3206713A4
(de)
|
2014-10-14 |
2018-06-27 |
Armo Biosciences, Inc. |
Interleukin-15-zusammensetzungen und verwendungen davon
|
EA201700181A1
(ru)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
|
ES2941234T3
(es)
|
2014-10-22 |
2023-05-19 |
Armo Biosciences Inc |
Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
|
US9434778B2
(en)
|
2014-10-24 |
2016-09-06 |
Bristol-Myers Squibb Company |
Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
|
EP3215193B1
(de)
|
2014-11-06 |
2023-10-04 |
PharmaEssentia Corporation |
Dosierungsschema für pegyliertes interferon
|
US20160151511A1
(en)
|
2014-12-02 |
2016-06-02 |
Antriabio, Inc. |
Proteins and protein conjugates with increased hydrophobicity
|
CN104491843B
(zh)
*
|
2015-01-23 |
2017-09-12 |
石药集团百克(山东)生物制药有限公司 |
一种聚乙二醇修饰的rhG‑CSF活性药物组合物
|
HRP20211824T1
(hr)
|
2015-01-28 |
2022-03-04 |
Ra Pharmaceuticals, Inc. |
Modulatori aktivnosti komplementa
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
TWI708611B
(zh)
*
|
2015-03-03 |
2020-11-01 |
香港商南沙生物科技(香港)有限公司 |
聚乙二醇化介白素-11之組合物及方法
|
CN108136001B
(zh)
|
2015-04-03 |
2022-07-29 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
JP6525171B2
(ja)
|
2015-04-13 |
2019-06-05 |
国立研究開発法人産業技術総合研究所 |
環状化サイトカイン及びその製法
|
ES2903448T3
(es)
|
2015-05-01 |
2022-04-01 |
Allysta Pharmaceuticals Inc |
Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares
|
JP7121496B2
(ja)
|
2015-05-28 |
2022-08-18 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
癌治療で使用するためのペグ化インターロイキン-10
|
WO2017024285A2
(en)
|
2015-08-06 |
2017-02-09 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
AU2016312510A1
(en)
|
2015-08-25 |
2018-03-08 |
Armo Biosciences, Inc. |
Methods of using Interleukin-10 for treating diseases and disorders
|
RU2738416C2
(ru)
|
2015-09-18 |
2020-12-14 |
Юниверсити Оф Миязаки |
Длительно действующее производное адреномедуллина
|
CA3000697A1
(en)
|
2015-10-01 |
2017-04-06 |
Amgen Inc. |
Treatment of bile acid disorders
|
US10935276B2
(en)
|
2015-10-20 |
2021-03-02 |
Steven Michalski |
Air mixing device
|
RU2021132347A
(ru)
|
2015-12-08 |
2022-03-24 |
Байомарин Фармасьютикал Инк. |
Применение вариантов натрийуретического пептида типа c для лечения остеоартрита
|
HUE061759T2
(hu)
|
2015-12-16 |
2023-08-28 |
Ra Pharmaceuticals Inc |
Komplement aktivitás modulátorai
|
SG11201806496SA
(en)
|
2016-01-29 |
2018-08-30 |
Heyue Zhou |
Antigen binding proteins that bind pd-l1
|
US10519250B2
(en)
|
2016-08-01 |
2019-12-31 |
Xoma (Us) Llc |
Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
|
CA3038679A1
(en)
|
2016-09-28 |
2018-04-05 |
Xoma (Us) Llc |
Antibodies that bind interleukin-2 and uses thereof
|
WO2018106859A1
(en)
|
2016-12-07 |
2018-06-14 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
TW201837051A
(zh)
|
2017-02-08 |
2018-10-16 |
美商必治妥美雅史谷比公司 |
包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
|
SG10202110492YA
(en)
|
2017-06-22 |
2021-11-29 |
Catalyst Biosciences Inc |
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
|
KR102020995B1
(ko)
|
2017-10-30 |
2019-09-16 |
한국코러스 주식회사 |
콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
|
CN111094462A
(zh)
|
2017-12-26 |
2020-05-01 |
贝克顿·迪金森公司 |
深紫外线可激发的水溶剂化聚合物染料
|
US11732016B2
(en)
|
2017-12-27 |
2023-08-22 |
Council Of Scientific & Industrial Research |
Polypeptide exhibiting granulocyte-colony stimulating factor activity
|
EP3765484A4
(de)
*
|
2018-03-14 |
2021-12-22 |
Ba, Yong |
Pegylierte gefrierschutzproteine und verfahren zu deren herstellung und verwendung
|
JP2021519841A
(ja)
|
2018-03-30 |
2021-08-12 |
ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company |
ペンダントクロモフォアを有する水溶性ポリマー色素
|
AU2019260418A1
(en)
|
2018-04-24 |
2020-11-19 |
Amgen Inc. |
Method for making injectable pharmaceutical compositions
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
KR102167755B1
(ko)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
|
CA3107332A1
(en)
|
2018-07-22 |
2020-01-30 |
Bioasis Technologies Inc. |
Treatment of lymphatic metastases
|
AU2019337610A1
(en)
|
2018-09-11 |
2021-05-06 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
EP3867265A1
(de)
|
2018-10-19 |
2021-08-25 |
Ambrx, Inc. |
Interleukin-10 -polypeptid-konjugate, dimere davon und ihre verwendungen
|
CN113661239A
(zh)
|
2018-12-28 |
2021-11-16 |
催化剂生物科学公司 |
经修饰的尿激酶型纤溶酶原激活物多肽和使用方法
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
WO2020168017A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
US10882954B2
(en)
|
2019-04-11 |
2021-01-05 |
Sunbio Inc. |
Tertiary alkoxy polyethylene glycol and derivatives thereof
|
JP7281140B2
(ja)
*
|
2019-04-15 |
2023-05-25 |
日油株式会社 |
生体関連物質とブロックポリマーとの結合体、および前記結合体を得るためのブロックポリマー誘導体
|
JP2022529943A
(ja)
|
2019-04-15 |
2022-06-27 |
クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー |
がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物
|
CA3174114A1
(en)
|
2020-03-11 |
2021-09-16 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
US20230204597A1
(en)
|
2020-03-20 |
2023-06-29 |
Amgen Inc. |
Determination of free n-terminus of pegfilgrastim using an acid protease
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
US20230302150A1
(en)
|
2020-08-20 |
2023-09-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
US11602598B1
(en)
*
|
2020-08-27 |
2023-03-14 |
Fresenius Kabi Deutschland Gmbh |
Prefilled syringe with pegfilgrastim having optimized dose and methods related thereto
|
CN112710826A
(zh)
*
|
2020-11-17 |
2021-04-27 |
北京九强生物技术股份有限公司 |
一种提高试剂稳定性的包被和封闭方法
|
US11952461B2
(en)
|
2021-03-22 |
2024-04-09 |
Sunbio, Inc. |
Siloxy polyethylene glycol and derivatives thereof
|
IL307282A
(en)
|
2021-04-03 |
2023-11-01 |
Ambrx Inc |
Antidote conjugates against HER2 and their applications
|
CN113214328B
(zh)
*
|
2021-05-08 |
2022-06-28 |
宁波经济技术开发区弘翔生化科技有限公司 |
一种双水相体系以及基于双水相体系的单糖分离方法
|
EP4155349A1
(de)
|
2021-09-24 |
2023-03-29 |
Becton, Dickinson and Company |
Wasserlösliche gelbe grünabsorbierende farbstoffe
|
WO2024007016A2
(en)
|
2022-07-01 |
2024-01-04 |
Beckman Coulter, Inc. |
Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
|
WO2024044327A1
(en)
|
2022-08-26 |
2024-02-29 |
Beckman Coulter, Inc. |
Dhnt monomers and polymer dyes with modified photophysical properties
|